Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries - Findings from the EUROASPIRE IV survey

Atherosclerosis

Volumn 246, Issue , 2016, Pages 243-250

  Reiner, Z ^a   De Backer, G ^b   Fras, Z ^c   Kotseva, K ^d   Tokgozoglu L ^e   Wood, D ^d   De Bacquer, D ^b  

^a KBC Zagreb   (Croatia)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^e HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Coronary heart disease; EUROASPIRE; LDL Cholesterol; Non HDL Cholesterol; Secondary prevention; Statins

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EUROPEAN; FEMALE; HEALTH SURVEY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RISK FACTOR; ADOLESCENT; BLOOD; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CORONARY DISEASE; CROSS-SECTIONAL STUDY; DRUG UTILIZATION REVIEW; DYSLIPIDEMIAS; EUROPE; HEALTH CARE DISPARITY; HEALTH CARE SURVEY; HOSPITAL DISCHARGE; MIDDLE AGED; MULTICENTER STUDY; PRACTICE GUIDELINE; PRESCRIPTION; PROTOCOL COMPLIANCE; RISK ASSESSMENT; SECONDARY PREVENTION; TIME FACTOR; TREATMENT OUTCOME; TRENDS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION REVIEW; DYSLIPIDEMIAS; EUROPE; FEMALE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HEALTHCARE DISPARITIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; PATIENT DISCHARGE; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84955108728     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.01.018     Document Type: Article

References (38)

1. Graham I., Cooney M.T., Bradley D., Dudina A., Reiner Ž. Dyslipidemias in the prevention of cardiovascular disease: risks and causality. Curr. Cardiol. Rep. 2012, 14:709-720.
2. Perk J., De Backer G., Gohlke H., et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Atherosclerosis 2012, 223:1-68.
3. Baigent C., Blackwell L., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681. Cholesterol Treatment Trialists' (CTT) Collaboration.
4. Reiner Ž Statins in the primary prevention of cardiovascular disease. Nat. Rev. Cardiol. 2013, 10(8):453-464.
5. Stone N.J., Robinson J.G., Lichtenstein A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American heart association task force on practice guidelines. Circulation 2014, 129:S1-S45.
6. Reiner Ž Catapano AL., De Backer G., et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European atherosclerosis society (EAS). Eur. Heart J. 2011, 32:1769-1818.
7. Reiner Ž Combined therapy in the treatment of dyslipidemia. Fundam. Clin. Pharmacol. 2010, 24:19-28.
8. Reiner Ž Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Nutr. Metab. Cardiovasc Dis. 2013, 23(9):799.
9. Bohula E.A., Giugliano R.P., Cannon C.P., Zhou J., Murphy S.A., White J.A., Tershakovec A.M., Blazing M.A., Braunwald E. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity c-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation 2015, 132(13):1224-1233.
10. Kotseva K., Wood D., De Bacquer D., De Backer G., Rydén L., Jennings C., Gyberg V., Amouyel P., Bruthans J., Castro Conde A., Cífková R., Deckers J.W., De Sutter J., Dilic M., Dolzhenko M., Erglis A., Fras Z., Gaita D., Gotcheva N., Goudevenos J., Heuschmann P., Laucevicius A., Lehto S., Lovic D., Miličić D., Moore D., Nicolaides E., Oganov R., Pajak A., Pogosova N., Reiner Ž., Stagmo M., Störk S., Tokgözoğlu L., Vulic D. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur. J. Prev. Cardiol. 2015 Feb 16, on behalf of the EUROASPIRE Investigators, pii: 2047487315569401. [Epub ahead of print]. 10.1177/2047487315569401.
11. Monaldi B., Bologna G., Costa G.G., D'Agostino C., Ferrante F., Filice M., Grion A.M., Mingarelli A., Paloscia L., Tettamanti R., Veronesi C., Degli Esposti L. Adherence to statin treatment following a myocardial infarction: an Italian population-based survey. Clin. Outcomes Res. 2015, 7:273-280.
12. Reiner Ž., Tedeschi-Reiner E. Prevalence and types of persistent dyslipidemia in patients treated with statins. Croat. Med. J. 2013, 54:339-345.
13. Šimić I., Reiner Ž. Adverse effects of statins - myths and reality. Curr. Pharm. Des. 2015, 21:1220-1226.
14. Reiner Ž., Sonicki Z., Tedeschi-Reiner E. Physicians' perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey. Atherosclerosis 2010, 213:598-603.
15. Reiner Ž Sonicki Z., Tedeschi-Reiner E. Public perceptions of cardiovascular risk factors in Croatia: the PERCRO survey. Prev. Med. 2010, 51:494-496.
16. Simpson R.J., Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review. J. Clin. Lipidol. 2010, 4(6):462-471.
17. De Vera M.A., Bhole V., Burns L.C., Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br. J. Clin. Pharmacol. 2014, 78(4):684-698.
18. Perreault S., Blais L., Lamarre D., et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br. J. Clin. Pharmacol. 2005, 59:564-573.
19. Mann D.M., Woodward M., Muntner P., Falzon L., Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann. Pharmacother. 2010, 44(9):1410-1421.
20. Reiner Ž Resistance and intolerance to statins. Nutr. Metab. Cardiovasc Dis. 2014, 24:1057-1066.
21. Cohen J.D., Brinton E.A., Ito M.K., Jacobson T.A. Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users. J. Clin. Lipidol. 2012, 6(3):208-215.
22. Redfors B., Angerås O., Råmunddal T., Petursson P., Haraldsson I., Dworeck C., Odenstedt J., Ioaness D., Ravn-Fischer A., Wellin P., Sjöland H., Tokgozoglu L., Tygesen H., Frick E., Roupe R., Albertsson P., Omerovic E. Trends in gender differences in cardiac care and outcome after acute myocardial infarction in Western Sweden: a report from the Swedish web system for enhancement of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). J. Am. Heart Assoc. 2015 Jul 14, s(7):e001995. 10.1161/JAHA.115.001995.
23. Lee J.H., Bae M.H., Yang D.H., Park H.S., Cho Y., Jeong M.H., Kim Y.J., Kim K.S., Hur S.H., Seong I.W., Cho M.C., Kim C.J., Chae S.C. Korea acute myocardial infarction registry investigators. Contemporary trends of optimal evidence-based medical therapy at discharge for patients surviving acute myocardial infarction from the Korea acute myocardial infarction registry. Clin. Cardiol. 2015, 38(6):350-356.
24. Sheppard J.P., Singh S., Fletcher K., et al. Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study. BMJ 2012, 345:e4535.
25. Reiner Ž Primary prevention of cardiovascular disease with statins in the elderly. Curr. Atheroscler. Rep. 2014, 16:420-426.
26. Upmeier E., Korhonen M.J., Helin-Salmivaara A., Huupponen R. Statin use among older finns stratified according to cardiovascular risk. Eur. J. Clin. Pharmacol. 2013, 69(2):261-267.
27. Knott R.J., Petrie D.J., Heeley E.L., Chalmers J.P., Clarke P.M. The effects of reduced copayments on discontinuation and adherence failure to statin medication in Australia. Health Policy 2015, 119(5):620-627.
28. Bergman Marković B., Kranjčević K., Reiner Ž., Milaković Blažeković S., Stojanović Špehar S. Drug therapy of cardiovascular risk factors: guidelines versus reality in primary health care service. Croat. Med. J. 2005, 46(6):944-989.
29. Mazalin Protulipac J., Sonicki Z., Reiner Ž. Cardiovascular disease (CVD) risk factors in older adults - perception and reality. Arch. Gerontol. Geriatr. 2015, 61(1):88-92.
30. Reiner Ž., De Bacquer D., Kotseva K., Prugger C., De Backer G., Wood D. Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey. Atherosclerosis 2013, 231(2):300-307. EUROASPIRE III Study Group.
31. Bangalore S., Fayyad R., Kastelein J.J., Laskey R., Amarenco P., DeMicco D.A., Waters D.D. 2013 cholesterol guidelines revisited: percent LDL cholesterol reduction or attained LDL cholesterol level or both for prognosis?. Am. J. Med. 2015 Nov 6, pii: S0002-9343(15)01029-3 [Epub ahead of print]. 10.1016/j.amjmed.2015.10.024.
32. Reiner Ž., Sonicki Z., Tedeschi-Reiner E. The perception and knowledge of cardiovascular risk factors among medical students. Croat. Med. J. 2012, 53(3):278-284.
33. Zannad F., Dallongeville J., Macfadyen R.J., et al. Prevention of cardiovascular disease guided by total risk estimations-challenges and opportunities for practical implementation: highlights of a cardiovascular clinical trialists (CVCT) workshop of the ESC working group on cardiovascular pharmacology and drug Therapy. Eur. J. Prev. Cardiol. 2012, 19:1454-1464.
34. Reiner Ž PCSK9 inhibitors - past, present and future. Expert Opin. Drug Metab. Toxicol. 2015, 11(10):1517-1521.
35. Boekholdt S.M., Arsenault B.J., Mora S., Pedersen T.R., LaRosa J.C., Nestel P.J., et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012, 307(12):1302-1309.
36. Bayturan O., Kapadia S., Nicholls S.J., Tuzcu E.M., Shao M., Uno K., et al. Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J. Am. Coll. Cardiol. 2010, 55(24):2736-2742.
37. Zambon A., Puato M., Faggin E., Grego F., Rattazzi M., Pauletto P. Lipoprotein remnants and dense LDL are associated with features of unstable carotid plaque: a flag for non-HDL-C. Atherosclerosis 2013, 230(1):106-109.
38. Cannon C.P., Blazing M.A., Giugliano R.P., McCagg A., White J.A., Theroux P., Darius H., Lewis B.S., Ophuis T.O., Jukema J.W., De Ferrari G.M., Ruzyllo W., De Lucca P., Im K., Bohula E.A., Reist C., Wiviott S.D., Tershakovec A.M., Musliner T.A., Braunwald E., Califf R.M. IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute cronary syndromes. N. Engl. J. Med. 2015, 372(25):2387-2397.